Kerstein David 4
4 · Theseus Pharmaceuticals, Inc. · Filed Feb 21, 2023
Insider Transaction Report
Form 4
Kerstein David
Chief Medical Officer
Transactions
- Award
Stock Option (right to buy)
2023-02-17+105,000→ 105,000 totalExercise: $11.42Exp: 2033-02-17→ Common Stock (105,000 underlying)
Footnotes (1)
- [F1]The options are subject to a service-based vesting requirement, which shall be satisfied over a four-year period with 25% of the options vesting on February 17, 2024 and 1/48th of the options vesting monthly thereafter, subject to the Reporting Person's continuous service with the issuer.